TGFB1 and neoplasm: In NSCLC, TFAP2A is implicated in promoting tumor-induced angiogenesis and inducing resistance to the anti-angiogenic effect of anlotinib via PDGFR, TGF-β, and VEGFR signaling pathways [65].